BioCentury | Dec 17, 2007
Regulation

Atrial fibrillation pipeline

Atrial fibrillation pipeline Atrial fibrillation pipeline Selected compounds in development for atrial fibrillation (AF). Company Product Description Indication Status Cardiome/Astellas Kynapid vernakalant Intravenous mixed ion channel antagonist AF Under review Solvay Pulzium tedisamil Intravenous multiple...
BC Week In Review | Mar 6, 2006
Clinical News

Neupro rotigotine regulatory update

EC approved an MAA for Neupro, a dopamine D2 receptor agonist patch, to treat Parkinson's disease (PD). Additionally, Schwarz received an approvable letter for Neupro to treat early stage PD in which FDA asked for...
BC Week In Review | Dec 19, 2005
Clinical News

Neupro rotigotine regulatory update

CHMP issued a positive opinion on the MAA for Neupro transdermal rotigotine patch to treat idiopathic Parkinson's disease (PD). Neupro is a dopamine D2 receptor agonist patch. Aderis Pharmaceuticals Inc. , Hopkinton, Mass.   Schwarz Pharma...
BioCentury | Aug 15, 2005
Finance

Ebb & Flow

Last week's IPO by Coley (COLY) was the first U.S. biotech IPO to price at the top of the range and then trade up in the aftermarket since small molecule company Theravance (THRX) in October...
BC Week In Review | Jul 25, 2005
Company News

Boston Life management update

Boston Life Sciences Inc. (BLSI), Boston, Mass.   Business: Neurology, Diagnostic   Hired: Noel Cusack as SVP of preclinical development, formerly CSO of Aderis Pharmaceuticals Inc.; and Kenneth Rice as CFO, EVP of finance and...
BC Week In Review | Jul 25, 2005
Company News

Aderis, Schwarz Pharma deal

Schwarz paid Aderis $67 million in cash to remove the royalties and milestones related to Neupro rotigotine that Schwarz would have owed Aderis. In 1998, Schwarz acquired worldwide rights to the dopamine D2 receptor agonist...
BC Extra | Jul 19, 2005
Company News

Boston Life Sciences names Rice CFO

BLSI hired Kenneth Rice as CFO, EVP of finance and administration and in-house counsel, effective July 1. He replaces Joseph Hernon, who will remain VP and secretary. Previously, Rice was CFO, VP and chief commercial...
BioCentury | Jan 10, 2005
Finance

Ebb & Flow

Last week saw two series D rounds go in opposite directions. Cancer play Nereus opted for a two-part financing, and maintains that having milestone-contingent money is important for discipline. On the flip side, drug delivery...
BC Extra | Jan 4, 2005
Financial News

First closing for NeoMed fund

NeoMed Management (Oslo, Norway) closed its fourth fund, NeoMed Innovation IV LP, at EUR 38 million ($51.6 million). The fund will invest in emerging healthcare and life sciences companies in the EU, Scandinavia, and to...
BioCentury | Oct 18, 2004
Product Development

A patch for Parkinson's

Schwarz Pharma AG 's Neupro rotigotine dopamine receptor agonist for Parkinson's disease may have an advantage over marketed compounds in the same class because it is administered once daily using a patch. By comparison, marketed...
Items per page:
1 - 10 of 74
BioCentury | Dec 17, 2007
Regulation

Atrial fibrillation pipeline

Atrial fibrillation pipeline Atrial fibrillation pipeline Selected compounds in development for atrial fibrillation (AF). Company Product Description Indication Status Cardiome/Astellas Kynapid vernakalant Intravenous mixed ion channel antagonist AF Under review Solvay Pulzium tedisamil Intravenous multiple...
BC Week In Review | Mar 6, 2006
Clinical News

Neupro rotigotine regulatory update

EC approved an MAA for Neupro, a dopamine D2 receptor agonist patch, to treat Parkinson's disease (PD). Additionally, Schwarz received an approvable letter for Neupro to treat early stage PD in which FDA asked for...
BC Week In Review | Dec 19, 2005
Clinical News

Neupro rotigotine regulatory update

CHMP issued a positive opinion on the MAA for Neupro transdermal rotigotine patch to treat idiopathic Parkinson's disease (PD). Neupro is a dopamine D2 receptor agonist patch. Aderis Pharmaceuticals Inc. , Hopkinton, Mass.   Schwarz Pharma...
BioCentury | Aug 15, 2005
Finance

Ebb & Flow

Last week's IPO by Coley (COLY) was the first U.S. biotech IPO to price at the top of the range and then trade up in the aftermarket since small molecule company Theravance (THRX) in October...
BC Week In Review | Jul 25, 2005
Company News

Boston Life management update

Boston Life Sciences Inc. (BLSI), Boston, Mass.   Business: Neurology, Diagnostic   Hired: Noel Cusack as SVP of preclinical development, formerly CSO of Aderis Pharmaceuticals Inc.; and Kenneth Rice as CFO, EVP of finance and...
BC Week In Review | Jul 25, 2005
Company News

Aderis, Schwarz Pharma deal

Schwarz paid Aderis $67 million in cash to remove the royalties and milestones related to Neupro rotigotine that Schwarz would have owed Aderis. In 1998, Schwarz acquired worldwide rights to the dopamine D2 receptor agonist...
BC Extra | Jul 19, 2005
Company News

Boston Life Sciences names Rice CFO

BLSI hired Kenneth Rice as CFO, EVP of finance and administration and in-house counsel, effective July 1. He replaces Joseph Hernon, who will remain VP and secretary. Previously, Rice was CFO, VP and chief commercial...
BioCentury | Jan 10, 2005
Finance

Ebb & Flow

Last week saw two series D rounds go in opposite directions. Cancer play Nereus opted for a two-part financing, and maintains that having milestone-contingent money is important for discipline. On the flip side, drug delivery...
BC Extra | Jan 4, 2005
Financial News

First closing for NeoMed fund

NeoMed Management (Oslo, Norway) closed its fourth fund, NeoMed Innovation IV LP, at EUR 38 million ($51.6 million). The fund will invest in emerging healthcare and life sciences companies in the EU, Scandinavia, and to...
BioCentury | Oct 18, 2004
Product Development

A patch for Parkinson's

Schwarz Pharma AG 's Neupro rotigotine dopamine receptor agonist for Parkinson's disease may have an advantage over marketed compounds in the same class because it is administered once daily using a patch. By comparison, marketed...
Items per page:
1 - 10 of 74